Investigational drug · Phase 2
ABI-2280
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Human Papillomavirus Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "ABI-2280"
First trial start
2024
Mar 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABI-2280", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Papillomavirus Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ABI-2280" as an intervention, largest first.
- Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal InsertsPivotal-lookingCompleted
Antiva BiosciencesIndustry
NCT06491446 · 141 participants · Start Mar 27, 2024 · Primary completion Oct 17, 2025
Drug: ABI-2280 · For: Human Papillomavirus Infection
Sites: Adelaide, Australia; Camberwell, Australia; Darlinghurst, Australia · 24 sites in all
Antiva BiosciencesIndustry
NCT05502367 · 44 participants · Start Sep 10, 2022 · Primary completion Oct 27, 2025
Drug: ABI-2280 Vaginal Tablet/Insert · For: Cervical Intraepithelial Neoplasia
Sites: Darlinghurst, Australia; Cusco, Peru; Lima, Peru · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.